95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study - WU, JINGYING; HU, WEI; DU, YIJUN; ZHANG, QIAN; ZHOU, RENPENG; ZHANG, QIN; QIN, HUILING; YE, ZI; XU, YIMEI; FENG, SHENG; SHU, CHANG; SHEN, YU; et al. (Diabetes (New York, N.Y.), 2023)
Keywords: Agonists; Body mass index; Body weight; Clinical trials; Dosage; Food availability; Food consumption; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucose tolerance; Insulin secretion; Metabolic syndrome; Pharmacodynamics; Pharmacokinetics; Placebos; Safety; Titration; Vomiting